Clinical

What we're reading, June 9, 2016: Philadelphia is poised to become the first major city to pass a soda tax; California raises its smoking age to 21; and the Obama administration looks to limit short-term health plans.

The German-Australian AML Study Group, one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes based on the harbored genetic mutations.

A poster presented at the annual meeting of the American Society of Clinical Oncology (ASCO) found that the cost per median month of survival for daratumumab was lower compared with 2 other novel treatments in multiple myeloma.

Even in a state with relatively few Medicaid restrictions on hepatitis C virus medications, a low number of patients requested treatment.

What we're reading, June 8, 2016: obesity rate among women reaches record high; abuse-resistant opioid recommended for approval by advisory panel; and Gilead does not owe Merck money in drug-patent dispute.

The Department of Justice has announced that Genentech and OSI Pharmaceuticals “will pay $67 million to resolve False Claim Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer.”

With only 3 medications FDA-approved to treat opioid addiction, patient access to these treatment options can be difficult, and each medication presents its own challenges, said Kelly J. Clark, MD, MBA, president elect of the American Society of Addiction Medicine.

Many patients 65 years or younger are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.

Can the Oncotype DX Breast Cancer Assay impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions asked by researchers at the University of Michigan, and the results presented during the annual meeting of the American Society of Clinical Oncology.

What we're reading, June 7, 2016: opioid restrictions disproportionately affect older patients with chronic pain; Genentech and OSI Pharmaceuticals settle Tarceva lawsuit; and trouble raising Zika virus funds.

As the name and meaning of specialty medications have grown over time, so too has the importance of these pharmaceuticals, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.

The American Society of Clinical Oncology’s first-ever clinical trial is growing with the addition of its seventh and eighth pharmaceutical companies, Bayer and Merck, and 30 additional trial participants.

A session at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO) provided an overview of ASCO's recently updated value framework and their quality program, the Quality Oncology Practice Initiative.

What we're reading, June 6, 2016: Vice President Joe Biden will announce the launch of an open-access cancer research database, and a new bill in Congress would allow companies to repurpose existing drugs for rare diseases.

While several clinical trials have tried to identify a programmed death-1 or programmed death ligand-1 expression—dependent response, it’s been an uphill task. During one of the sessions at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarker-based treatment.

During a session on the second day of the annual meeting of the American Society of Clinical Oncology, experts discussed treating patients with chimeric antigen receptor T cells (CAR-T cells).

A secondary analysis of data from the TECOS trial of sitagliptin finds that the drug does not affect the risk for heart failure hospitalization or related adverse clinical outcomes in people with type 2 diabetes

New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.

As immunotherapy continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination. During a session on the second day of the ongoing annual meeting of the American Society of Clinical Oncology, in Chicago, IL, the results from some of these trials were shared.

On the first day of the annual meeting of the American Society of Clinical Oncology, healthcare experts from the United States, Canada, and the United Kingdom, compared and contrasted the care models that are widely adopted in each nation.

A study presented at the ongoing European Obesity Summit has confirmed a correlation between the risk of developing high grade prostate cancer and high body mass index and waist circumference.

What we're reading, June 3, 2016: Florida's crackdown on opioid prescriptions is working; some California physicians are uneasy about prescribing lethal doses to terminally ill patients; and Ashish Jha, MD, MPH, shines a spotlight on the real culprit of preventable medical errors.

More than 400 comments were sent in regarding the American Society of Clinical Oncology (ASCO)'s Value Framework, and they will be incorporated as the framework evolves, explained Stephen Grubbs, MD, vice president for clinical affairs at ASCO.

One of the important findings from the American Society of Clinical Oncology’s report is that cancer mortality has gone down, said Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.

Interim results from the ongoing CANVAS (Canagliflozin Cardiovascular Assessment Study) clinical trial have found an increased risk of leg and foot amputations associated with the popular diabetes medication.